ストックスクリーナーアプリを入手
42.19
5.63%
2.25
前日終値:
$39.94
開ける：
$40
24時間の取引高:
4.27M
Relative Volume:
1.79
時価総額：
$7.03B
収益：
$1.56B
当期純損益:
$152.72M
株価収益率:
46.91
EPS:
0.8994
ネットキャッシュフロー:
$221.80M
1週間 パフォーマンス:
+14.65%
1か月 パフォーマンス:
+25.16%
6か月 パフォーマンス:
+42.63%
1年 パフォーマンス:
+39.47%
1日の値動き範囲:
$39.64
$42.83
1週間の範囲:
$36.49
$42.83
52週間の値動き範囲:
$25.16
$42.83
Alkermes Plc Stock (ALKS) Company Profile
Compare ALKS vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
42.19 | 6.66B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
15.96 | 51.03B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.32 | 40.20B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.06 | 40.78B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
77.69 | 32.81B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
556.82 | 23.86B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2025-11-11 | 開始されました | Truist | Buy |
| 2025-09-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2025-06-17 | アップグレード | UBS | Neutral → Buy |
| 2025-05-28 | 開始されました | Needham | Buy |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | アップグレード | UBS | Sell → Neutral |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-11-05 | アップグレード | Stifel | Hold → Buy |
| 2024-06-17 | 開始されました | TD Cowen | Buy |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-20 | ダウングレード | UBS | Neutral → Sell |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 開始されました | UBS | Neutral |
| 2022-11-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 開始されました | Piper Sandler | Neutral |
| 2022-04-22 | 再開されました | Goldman | Buy |
| 2022-04-20 | 開始されました | Goldman | Buy |
| 2022-01-27 | アップグレード | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 開始されました | Citigroup | Neutral |
| 2021-10-07 | アップグレード | Jefferies | Hold → Buy |
| 2021-09-02 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-10-15 | アップグレード | Mizuho | Neutral → Buy |
| 2020-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2020-02-14 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-01-31 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-31 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-12-19 | ダウングレード | Goldman | Neutral → Sell |
| 2018-12-14 | 開始されました | Wolfe Research | Underperform |
| 2018-12-13 | ダウングレード | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 開始されました | Piper Jaffray | Neutral |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Alkermes Plc (ALKS) 最新ニュース
Tranche Update on Alkermes plc's Equity Buyback Plan announced on February 15, 2024. - marketscreener.com
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout
Alkermes (ALKS) finance VP exercises options and sells 16,217 shares - Stock Titan
Alkermes Plc Hits New 52-Week High at $40.78, Up 65% - Markets Mojo
Alkermes showcases data from psychiatry portfolio and sleep research into real world patient experience at spring 2026 scientific conferences - MSN
Alkermes plc stock (IE00B56GVS15): 52-week high after Q1 beat - AD HOC NEWS
Alkermes PLC (ALKS) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 76/100 - GuruFocus
Alkermes stock hits 52-week high at 39.57 USD By Investing.com - Investing.com Nigeria
Alkermes stock hits 52-week high at 39.57 USD - Investing.com
Alkermes to showcase leadership in psychiatry and orexin biology with new data at the American Society of Clinical Psychopharmacology annual meeting - MSN
New orexin data on narcolepsy, schizophrenia at ASCP meeting - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: Unlocking Potential With A 23.47% Upside - DirectorsTalk Interviews
Alkermes (ALKS) director logs RSU exercise, tax withholding and new equity grants - Stock Titan
Alkermes (ALKS) director gets new RSUs, options and tax withholding - Stock Titan
[Form 4] Alkermes plc. Insider Trading Activity - Stock Titan
Alkermes (NASDAQ: ALKS) director reports RSU vesting, option grant and tax-share withholding - Stock Titan
[Form 4/A] Alkermes plc. Amended Insider Trading Activity - Stock Titan
Alkermes (ALKS) director receives equity awards and corrects vesting terms - Stock Titan
Alkermes (ALKS) director reports RSU vesting, tax withholding and new stock options - Stock Titan
Alkermes (NASDAQ: ALKS) director logs RSU exercise, new option and RSU grants - Stock Titan
Avoiding Lag: Real-Time Signals in (ALKS) Movement - Stock Traders Daily
Alkermes Shareholders Approve Amended Stock Incentive Plan - The Globe and Mail
LYBALVI data detail real-world relapse and ER visit outcomes - Stock Titan
Alkermes (ALKS) shareholders approve 2018 equity plan, directors and auditor - Stock Titan
Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge - TipRanks
Alkermes plc (ALKS) Stock Analysis: Uncovering a 21% Upside Potential in Biopharmaceutical Innovation - DirectorsTalk Interviews
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises - MSN
Alkermes plc stock (IE00B56GVS15): M&A deal with Avadel and fresh analyst signals put focus on futur - AD HOC NEWS
Alkermes plc stock (IE00B56GVS15): focus shifts after oncology spin-off and latest quarterly figures - AD HOC NEWS
Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline - TipRanks
T. Rowe Price (NASDAQ: ALKS) holds 4.66M shares, 2.8% stake - Stock Titan
Alkermes Reports Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia - Sleep Review
What is HC Wainwright's Estimate for Alkermes Q2 Earnings? - MarketBeat
Alkermes plc $ALKS Shares Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Alkermes stock hits 52-week high at $38.94 By Investing.com - Investing.com South Africa
Alkermes plc stock (IE00B56GVS15): Baird raises price target to $48 - AD HOC NEWS
Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Alkermes reports encouraging data from Phase III study of Lumryz - Clinical Trials Arena
Alkermes stock hits 52-week high at $38.94 - Investing.com
ALKS Maintained by Baird -- Price Target Raised to $48.00 - GuruFocus
Alkermes (NASDAQ:ALKS) Price Target Raised to $48.00 - MarketBeat
Alkermes Gains Strength On Strong Execution And Strategic Diversification - RTTNews
Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH - Citeline News & Insights
Alkermes Earnings Surprise Keeps Nasdaq Composite Watching - Kalkine Media
Alkermes posts late-stage trial win for Lumryz in new sleep disorder - MSN
Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings - simplywall.st
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles - Benzinga
Investors Can Find Comfort In Alkermes' (NASDAQ:ALKS) Earnings Quality - 富途牛牛
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023 - Quantisnow
Positive Phase 3 Results for Alkermes (ALKS) LUMRYZ in Treating Hypersomnia - GuruFocus
Alkermes (ALKS) Shares Rise on Positive Sleep Disorder Therapy T - GuruFocus
Alkermes Plc (ALKS) 財務データ
収益
当期純利益
現金流量
EPS
Alkermes Plc (ALKS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Parisi Samuel Joseph | VP, Finance (Interim PAO) |
May 29 '26 |
Sale |
42.36 |
16,217 |
687,007 |
7,717 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. |
May 04 '26 |
Sale |
33.20 |
2,034 |
67,529 |
231,558 |
0.81%
0.87%
大文字化:
|
ボリューム (24 時間):